Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Ninerafaxstat - ...

MedChemExpress - Model Ninerafaxstat - 2254741-41-6

Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases[1][2].

Ninerafaxstat

MCE China：Ninerafaxstat

Brand：MedChemExpress (MCE)

Cat. No.HY-139577

CAS：2254741-41-6

Synonyms：IMB-1018972; IMB-101

Purity：90.94%

Storage：Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases.

In Vitro：Ninerafaxstat can reduce myocardial steatosis, improve left ventricular diastolic filling and myocardial energetics[1].

In Vivo：Ninerafaxstat (30 mg/kg; once daily; 4 weeks; via osmotic minipump) can improve left ventricular systolic function and reduce left ventricular end diastolic pressure (LVEDP) and myocardial fibrosis in a mouse model of heart failure after myocardial infarction[2].

IC50 & Target：3-KAT, fatty acid oxidation[1]. In Vitro Ninerafaxstat can reduce myocardial steatosis, improve left ventricular diastolic filling and myocardial energetics[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ninerafaxstat Related Antibodies

References：

[1]. Moritz Hundertmark MD, et al. Kiosk 11R-TC-08 - Ninerafaxstat Modulates Cardiac Energy Metabolism in Cardio-metabolic Syndromes: A Mechanistic, Hyperpolarized MR Trial. Journal of Cardiovascular Magnetic Resonance. 2024; 26: 100325.

[2]. Paul Chamberlin, et al. IMB-1018792, A NOVEL FIRST-IN CLASS PARTIAL FATTY ACID OXIDATION INHIBITOR IMPROVES CARDIAC REMODELING AND FUNCTION POST-MYOCARDIAL INFARCTION. J Am Coll Cardiol. 2021 May 11;77(18):539.

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。